<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks? — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks?</h1>
      <div class="meta">2025-09-15 06:07:58+00:00 UTC</div>
      <ul>
        <li>Further, its non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7%.</li>
        <li>RMD’s mean price target of $289.25 suggests a 7.1% upside potential from current price levels.</li>
        <li>ResMed’s overall net revenues for the quarter grew 10.2% year-over-year to $1.35 billion, surpassing the Street expectations by 1.9%.</li>
        <li>22 and is currently trading 8.1% below that peak.</li>
        <li>ResMed’s stock prices gained 2.7% in the trading session following the release of its impressive Q4 results on Jul.</li>
        <li>Moreover, ResMed has also significantly outperformed its peer, Becton, Dickinson and Company’s (BDX) 17.6% decline in 2025 and 20.7% plunge over the past 52 weeks.</li>
        <li>RMD stock prices have surged 18.1% in 2025 and 7.8% over the past 52 weeks, outpacing XLV’s marginal 39 bps uptick on a YTD basis and 11.4% decline over the past year.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/how-is-resmeds-stock-performance-compared-to-other-healthcare-stocks/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/m/18e5adce-bfb3-30fe-a075-7f55ac01f1bc/how-is-resmed%27s-stock.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=How+Is+ResMed%27s+Stock+Performance+Compared+to+Other+Healthcare+Stocks%3F%0A%E2%80%A2+Further%2C+its+non-GAAP+EPS+soared+22.6%25+year-over-year+to+%242.55%2C+exceeding+the+consensus+estimates+by+3.7%25.%0A%E2%80%A2+RMD%E2%80%99s+mean+price+target+of+%24289.25+suggests+a+7.1%25+upside+potential+from%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fhow-is-resmeds-stock-performance-compared-to-other-healthcare-stocks%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
